A new study published in MicrobiologyOpen reports the isolation and mechanistic validation of Mitsuokella jalaludinii strain PMC73, a gut commensal that its discoverers describe as a

The rationale for looking to the intestine as a therapeutic reservoir in gout rests on a long-recognized but often overlooked facet of urate physiology. While the kidneys excrete the great majority of uric acid each day, roughly one third of renal-independent elimination occurs through the gut, where commensal bacteria capable of degrading urate and its purine precursors participate in what researchers describe as an intestinal uricolytic axis. When this microbial community is intact, urate that is secreted into the intestinal lumen can be metabolized before reabsorption; when dysbiosis depletes these uricolytic populations, more purine substrate recirculates and the systemic urate burden climbs. This ecological perspective reframes hyperuricemia not merely as an enzymatic problem within host cells but as a breakdown in a metabolic partnership between host and microbiome, one that a well-chosen microbial therapeutic could theoretically restore.

The evolutionary context makes this microbial capacity especially interesting to gout researchers. Most mammals possess functional uricase, a hepatic enzyme that converts uric acid into the far more soluble compound allantoin, which is excreted readily in urine. Humans and certain other primates lost uricase activity through a series of mutations during the Miocene epoch, a change frequently attributed to the antioxidant properties of urate or to proposed survival advantages under purine-rich diets. The consequence, however, is that humans depend almost entirely on renal and intestinal excretion to maintain urate homeostasis, and any impairment of either route predisposes to hyperuricemia. Microorganisms retained their uricolytic enzymes, and the urate transporter and uricase machinery of gut bacteria have therefore become attractive targets for understanding how uric acid is naturally degraded outside the liver.

Purine metabolism provides a second, upstream point of microbial intervention. Dietary and endogenous purines are broken down through a cascade in which hypoxanthine is oxidized to xanthine and then to uric acid by xanthine oxidoreductase, the very enzyme targeted by allopurinol and febuxostat. Bacteria in the intestinal lumen can intercept this pathway at multiple levels: some taxa assimilate purine bases directly as nutrients, incorporating them into nucleic acid biosynthesis rather than allowing their conversion to urate; others express enzymes that funnel hypoxanthine and xanthine toward degradation or interconversion routes that bypass uric acid formation. A candidate strain capable of consuming hypoxanthine, as the Mitsuokella isolate was evaluated for, would in principle reduce the substrate available to host xanthine oxidase, offering an indirect complement to xanthine oxidase inhibitor drugs without sharing their hepatic mechanism of action.

The inflammatory arm of gout pathophysiology is equally central to the study’s logic. Monosodium urate crystals do not cause tissue damage simply through mechanical abrasion; they are recognized as danger signals by macrophage pattern recognition receptors, leading to assembly of the NLRP3 inflammasome, a multiprotein complex that activates caspase-1 and enables proteolytic maturation of interleukin-1 beta and interleukin-18. Mature interleukin-1 beta drives the intense neutrophil recruitment, pain, warmth, and swelling characteristic of an acute flare. Because the macrophage sits at the initiating step of this cascade, the RAW 264.7 cell line triggered by synthetic urate crystals provides a reductionist but informative system for asking whether a candidate treatment dampens inflammasome activation, suppresses cytokine release, or limits the oxidative burst that accompanies crystal phagocytosis. Reactive oxygen species generated during this response feed back positively on inflammasome activity, making antioxidant effects and anti-inflammatory effects mechanistically intertwined.

Preclinical models of this kind carry inherent limitations that temper expectations. A murine macrophage line, even one authenticated and mycoplasma-free, cannot reproduce the complexities of human joint biology: the contribution of synovial lining cells, resident mast cells, neutrophil extracellular traps, and the adaptive immune system are all absent. Species differences between murine and human inflammasome regulation are well documented, and doses of crystal or bacterial conditioning media that inhibit cytokine release in vitro may behave differently in vivo, where pharmacokinetics, gut colonization dynamics, and host immune status shape outcomes. For this reason, the macrophage experiments are best understood as mechanistic screening that establishes plausibility and identifies signaling pathways worth interrogating, rather than as proof of clinical efficacy, which will require animal models of hyperuricemia and, ultimately, controlled human studies.

The safety evaluation framework applied to new microbial candidates deserves attention because it differs substantially from conventional drug development. Genomic analysis serves as the first gate: the complete chromosome sequence allows identification of virulence factor genes, toxin-encoding elements, and acquired antibiotic resistance determinants that could compromise clinical use. Average nucleotide identity calculations against reference genomes confirm the taxonomic identity of the strain at species-level resolution, which matters because probiotic safety and function can be strain-specific rather than species-wide. Physical characterization, including assessment of bile tolerance, acid survival, adhesion properties, and hemolytic behavior, then addresses whether the organism can survive gastrointestinal transit and whether it behaves as a commensal rather than an opportunistic pathogen. This layered vetting reflects lessons from rare infections involving lactobacilli and other typically benign bacteria in profoundly immunocompromised patients.

The post-NGP framing articulated by the authors responds to a genuine bottleneck in microbiome therapeutics. Cultivation-independent sequencing surveys over the past fifteen years revealed that a large fraction of gut species had never been cultured in the laboratory, and many of the most immunologically and metabolically active commensals are strict anaerobes that die rapidly on exposure to oxygen. Next-generation probiotics such as Akkermansia muciniphila and Faecalibacterium prausnitzii demonstrated that these organisms can be tamed and formulated, but also highlighted practical obstacles: manufacturing live obligate anaerobes at industrial scale, protecting them through stomach acid and bile, and maintaining viability on the shelf remain unsolved engineering problems for many candidates. Concepts such as pasteurized bacterial preparations and defined bioactive fractions have emerged as workarounds, suggesting that a live organism may not even be necessary if the responsible molecular mediators can be identified.

This is where the boundary between probiotics, postbiotics, and the proposed post-NGP framework becomes conceptually significant. Postbiotics, as defined in a 2021 expert consensus, encompass inanimate microorganisms or their components and metabolites that confer health benefits, effectively decoupling the therapeutic effect from organism viability. The post-NGP idea, as described here, is less a product category than a discovery pipeline: it emphasizes systematic isolation through culturomics, genomic validation, and disease-targeted functional screening before any candidate advances. In gout specifically, such screening can be structured around measurable functional readouts, including the capacity of a strain to consume uric acid or hypoxanthine in defined medium, to modulate inflammasome signaling in immune cells, and to survive physiological stresses encountered during oral administration. This funnel-like design contrasts with older serendipitous approaches in which commercially available strains were repurposed and tested for whatever benefits happened to emerge.

The epidemiological backdrop amplifies the value of any new mechanistic option. Gout burden correlates strongly with metabolic syndrome, nonalcoholic fatty liver disease, and chronic kidney disease, creating a therapeutic dilemma in which patients who most need urate lowering are often those least able to tolerate or benefit from existing drugs, since several require dose adjustment or carry heightened risks in renal impairment. Allopurinol dosing in particular must be reduced in kidney disease, and failure to attain target serum urate levels remains the most common reason for treatment failure in routine practice. Adherence is another persistent obstacle: because urate-lowering therapy is prophylactic rather than symptomatic, and because initiating therapy can transiently provoke flares, many patients discontinue treatment within the first year. An intervention perceived as a natural commensal with a favorable safety profile could, at least hypothetically, improve acceptability, although this presumption awaits evidence from real-world adherence studies.

Regulatory pathways will ultimately shape whether microbiome-derived candidates reach patients. In many jurisdictions, live biotherapeutic products are now treated as a distinct class requiring manufacture under pharmaceutical-grade controls, strain identity confirmation, and demonstration of absence of transferable resistance genes, in addition to conventional efficacy trials. The characterization work reported for PMC73, including complete genome sequencing on a long-read platform, phylogenomic placement among Mitsuokella reference strains, and PCR-based screening for virulence determinants, aligns with the early stages of such a pathway. What remains ahead is the harder translational sequence: demonstration of urate-lowering in animal models of hyperuricemia, evaluation of anti-inflammatory efficacy in crystal-induced arthritis models, pharmacological assessment of colonization and persistence, and finally randomized clinical testing in hyperuricemic and gouty populations. The present study supplies the mechanistic foundation and safety profile that such a program requires, and it illustrates how systematically mining human gut commensals can surface candidates that conventional probiotic development, constrained to a handful of familiar genera, would never have encountered.

Subject of Research: A human gut-derived bacterial strain, Mitsuokella jalaludinii PMC73, evaluated as a next-generation probiotic candidate for lowering uric acid and treating gout.

Article Title: A Post–NGP Mitsuokella jalaludinii as a Therapeutic Candidate for Gout

Article References: Hossain, M. S., Kim, S., Aziz, M. T., Ahmed, I., Shuvo, M. S. H., Yang, H., Jang, Y., Kim, M., Jang, S., Kim, Y., Oh, S., Nam, Y., Seo, H., & Song, H.-Y. (2026). A Post–NGP Mitsuokella jalaludinii as a Therapeutic Candidate for Gout. MicrobiologyOpen, 15(5), Article e70410. https://doi.org/10.1002/mbo3.70410

Image Credits: AI Generated

DOI: 10.1002/mbo3.70410

Keywords: gout, hyperuricemia, Mitsuokella jalaludinii, next-generation probiotics, gut microbiome, uric acid, NLRP3 inflammasome, xanthine oxidase, URAT1, postbiotics, RAW 264.7 macrophages, MicrobiologyOpen

The review, authored by Mohammad Ali Mahdiabadi, Asma Moghaddam, and Nafiseh Erfanian, synthesizes evidence that microbiome-derived tryptophan metabolites act as endogenous ligands for the aryl hydrocarbon receptor, or AhR, a transcription factor long studied as a sensor of environmental toxins but now recognized as a central regulator of intestinal homeostasis. In its resting state, AhR sits in the cytoplasm bound to a complex of chaperone proteins. When a ligand binds, the receptor moves into the nucleus, pairs with the AhR nuclear translocator, and switches on genes involved in epithelial maintenance, immune regulation, and detoxification. The gut bacteria supply a steady stream of these ligands: indole-3-aldehyde, indole-3-propionic acid, indole-3-lactic acid, and indole-3-acetic acid, all produced from tryptophan by enzymes such as tryptophanase distributed across Lactobacillus, Clostridium, Bifidobacterium, Bacteroides, and Escherichia coli species.

The foundational observation came from Zelante and colleagues in 2013, who showed that when dietary tryptophan is plentiful, gut lactobacilli shift toward tryptophan catabolism and produce indole-3-aldehyde, which drives AhR-dependent production of interleukin-22. This cytokine, secreted by innate lymphoid cells type 3 and T helper 17 cells, promotes epithelial regeneration, antimicrobial peptide output, and goblet cell function. Later work extended the template to tight junction preservation, mucus maintenance, and intestinal stem cell renewal, establishing the microbiota-tryptophan-AhR axis as a mechanistic linchpin of mucosal health.

Each major metabolite has now been dissected in preclinical colitis models. Indole-3-aldehyde, produced notably by Lactobacillus reuteri, reduces inflammatory cytokines such as interleukin-6, restores the tight junction proteins zonula occludens-1 and occludin, and improves measures of barrier integrity in dextran sulfate sodium colitis. Interestingly, two studies report different degrees of AhR dependence: one found the protection only partially dependent on the receptor, while a more recent analysis documented a strictly AhR- and AMPK-dependent mechanism, with efficacy nearly abolished by receptor inhibition. The discrepancy, the review suggests, likely reflects differences in dosing, treatment duration, and model responsiveness rather than contradictory biology, underscoring that receptor dependence is not an all-or-none property even for a single ligand.

Indole-3-propionic acid, efficiently produced by Clostridium sporogenes, restores tight junction proteins and induces interleukin-22 in ulcerative colitis models, and metabolomic studies consistently find it depleted in IBD patients in correlation with disease severity. Yet its pharmacology is complicated: recent work indicates it can also act directly on heat shock protein 70 to trigger apoptosis of inflammatory Th1 and Th17 cells, independently of AhR or the pregnane X receptor it additionally engages. Indole-3-lactic acid from Lactiplantibacillus plantarum activates both AhR and the antioxidant regulator Nrf2 while suppressing nuclear factor-kappa B, coordinating barrier protection and anti-inflammatory signaling through a single metabolite. Indole-3-acetic acid, by contrast, retains anti-inflammatory activity even when AhR is pharmacologically blocked, showing that at least some protective effects of the indole class operate through receptor-independent routes such as heme oxygenase-1 induction and free radical scavenging.

Downstream of AhR, the review maps an integrated signaling network rather than a simple linear cascade. The AhR-AMPK axis links metabolite sensing to autophagy and mitochondrial resilience in epithelial cells. AhR-Nrf2 crosstalk, though not a strictly hierarchical relationship, induces antioxidant enzymes including superoxide dismutase, catalase, and heme oxygenase-1, blunting the oxidative stress that drives NF-kappa B activation. AhR signaling also directly induces interleukin-22 transcription in immune cells and upregulates the interleukin-10 receptor on epithelia, amplifying anti-inflammatory STAT3 signaling. Finally, AhR-dependent reduction of myosin light chain phosphorylation relaxes the actomyosin cytoskeleton, easing junctional tension and lowering paracellular permeability, the hallmark of the so-called leaky gut.

The review’s most conceptually important contribution may be its insistence that this axis is bidirectional. Active inflammation induces indoleamine 2,3-dioxygenase 1, which diverts tryptophan away from microbial indole synthesis and into the host kynurenine pathway, further depleting protective AhR ligands precisely when the barrier needs them most. Dysbiosis in IBD simultaneously strips away the metabolite-producing taxa themselves, including Lactobacillus, Clostridium clusters, and Allobaculum species. The result is a self-reinforcing loop in which inflammation suppresses the very metabolites that would repair the tissue damage inflammation causes, and CARD9 deficiency, a human genetic risk factor for Crohn’s disease, has been shown to impair this axis by reducing AhR ligand-producing commensals.

Crucially, the authors caution that AhR activation is not uniformly beneficial. Microbial indoles are weak, rapidly metabolized agonists that produce the transient, low-amplitude receptor engagement compatible with tissue repair. Host-derived kynurenine metabolites, or sustained high-affinity activation by compounds such as dioxin, can drive immunosuppressive, barrier-impairing, or even pro-tumorigenic programs. Cell-type-specific transcriptional landscapes add further complexity, and in autoimmune models high-affinity ligands can promote Th17 differentiation, a potentially inflammation-amplifying outcome whose relevance for microbiota-derived indoles remains incompletely characterized. Therapeutic strategies, the review argues, must therefore be ligand-selective, replicating physiological kinetics rather than broadly amplifying AhR signaling.

On the translational front, human evidence remains supportive but limited. Multiple metabolomic cohorts have independently confirmed reduced fecal indole-3-acetate and indole-3-propionate in IBD patients, and direct tissue studies show that AhR expression is reduced in IBD mucosa while remaining functionally responsive to agonist stimulation. A randomized trial of indigo naturalis, an AhR-ligand preparation, achieved significant mucosal healing in ulcerative colitis but was halted early over pulmonary safety concerns, providing proof of concept without an approved therapy. No randomized human trial has yet tested purified indole metabolites, defined probiotic strains, or postbiotic formulations targeting this axis, and most mechanistic data derive from the acute DSS colitis model, which poorly replicates the chronic, immune-mediated pathology of human disease.

The authors propose postbiotics, standardized preparations of purified metabolites such as indole-3-aldehyde, indole-3-propionic acid, and indole-3-lactic acid, as the most practical near-term strategy, offering dose standardization, stability, and direct mechanistic targeting compared with live probiotics. Compounds such as berberine and ganoderic acid A, which enhance endogenous microbial tryptophan metabolism, represent indirect alternatives. But the review closes with measured language: targeting the microbial tryptophan-AhR axis is biologically compelling yet clinically unproven, and its translation will depend on well-designed interventional trials, standardized metabolomic methodology, careful attention to ligand selectivity, and honest reckoning with the feedback loop through which inflammation itself sabotages the repair machinery. Until those data arrive, the trillions of bacteria metabolizing a single dietary amino acid remain both the most promising and the least clinically validated allies in the fight against inflammatory bowel disease.

Subject of Research: Microbiome-derived tryptophan metabolites as ligands of the aryl hydrocarbon receptor that regulate epithelial barrier integrity in inflammatory bowel disease.

Article Title: Microbiome‐Derived Tryptophan Metabolites Regulate AhR Signaling to Restore Epithelial Barrier Integrity in Inflammatory Bowel Disease

Article References: Mahdiabadi, M. A., Moghaddam, A., & Erfanian, N. (2026). Microbiome‐Derived Tryptophan Metabolites Regulate AhR Signaling to Restore Epithelial Barrier Integrity in Inflammatory Bowel Disease. MicrobiologyOpen, 15(5), Article e70386. https://doi.org/10.1002/mbo3.70386

Image Credits: AI Generated

DOI: 10.1002/mbo3.70386

Keywords: inflammatory bowel disease, gut microbiome, tryptophan metabolism, aryl hydrocarbon receptor, indole metabolites, epithelial barrier, tight junctions, interleukin-22, postbiotics, dysbiosis, microbiome-targeted therapy, Microbiome

Obesity currently affects more than one billion people worldwide and is classified by the World Health Organization as a chronic, multifactorial disease defined by the excessive accumulation of adipose tissue. Its consequences reach far beyond body weight, extending into type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease and several cancers. The global economic burden is projected to reach trillions of US dollars annually by 2035. Yet existing treatments remain imperfect. Lifestyle interventions suffer from poor long-term adherence and frequent weight regain; pharmacological options such as GLP-1 receptor agonists and orlistat carry side effects ranging from gastrointestinal distress to cardiovascular risks, along with substantial costs; and bariatric surgery, while effective, is invasive and accessible to only a small fraction of those who need it. This treatment gap has driven growing scientific interest in food-derived bioactives as safer, more accessible complements or alternatives.

Rhizomes—the underground stems of plants such as turmeric (Curcuma longa), ginger (Zingiber officinale) and kencur (Kaempferia galanga)—are dense repositories of polyphenols, flavonoids and essential oils. However, many of their most celebrated compounds, including curcumin, suffer from notoriously poor water solubility, rapid systemic clearance and low oral bioavailability, which sharply constrain their therapeutic efficacy in conventional preparations. Fermentation offers a bioprocessing solution. When microorganisms such as lactic acid bacteria or filamentous fungi colonize the starch- and fibre-rich rhizome matrix, their enzymes cleave glycosidic and ester linkages, deconjugate polyphenols and generate structurally novel metabolites that simply do not exist in the raw plant. In one striking example documented in the review, fermentation of wild turmeric (Curcuma aromatica) with the fungus Rhizopus oligosporus produced l-carnitine de novo—a compound essential for transporting fatty acids into mitochondria for fat burning—reaching concentrations of up to 242 micrograms per gram, despite being absent from the unfermented substrate.

The metabolic by-products of this microbial transformation fall under the heading of postbiotics, a term defined by the International Scientific Association for Probiotics and Prebiotics as preparations of inanimate microorganisms and their components that confer a health benefit. Unlike probiotics, postbiotics do not require viable microorganisms, offering advantages in shelf stability, safety and standardization. Key postbiotic constituents generated during rhizome fermentation include short-chain fatty acids, bacteriocins, exopolysaccharides, bioactive peptides and biotransformed polyphenolic metabolites. The review’s authors are careful to note a nomenclature issue: because most included studies did not confirm microbial inactivation before administering their preparations, the team distinguishes throughout between “fermented rhizome products” as whole matrices and postbiotics in the strict sense, reserving the latter term for the specific bioactive metabolites hypothesized to mediate the observed effects.

To build this mechanistic framework, the researchers conducted the review under PRISMA guidelines, prospectively registering the protocol in PROSPERO. They searched four major databases—PubMed, Scopus, Web of Science and Embase—covering all records through April 2026, and screened 1307 initial records down to ten studies that met rigorous inclusion criteria. These comprised eight in vivo animal studies and two in vitro cell-culture studies spanning five rhizome species, with turmeric the most frequently investigated. Fermentation organisms were dominated by lactic acid bacteria, particularly Lactobacillus plantarum and L. paracasei, alongside filamentous fungi including Aspergillus oryzae, Eurotium cristatum and Rhizopus oligosporus. Animal models ranged from high-fat-diet-induced obesity in C57BL/6 mice and Sprague-Dawley rats to genetic obesity in ob/ob mice and spontaneous obesity in OLETF rats. Risk of bias was assessed using SYRCLE’s tool for animal studies and the ToxRTool for in vitro work, with both cell-culture studies achieving the highest reliability category.

Perhaps the most compelling evidence came from the six studies that directly compared fermented against unfermented preparations. In every single head-to-head comparison, the fermented product outperformed its unfermented counterpart on at least one assessed outcome. Fermented Rhizoma Atractylodis Macrocephalae more effectively reduced adipose tissue weight and improved serum triglycerides than the raw rhizome. Fermented turmeric suppressed weight gain and modulated gut microbiota more powerfully than unfermented turmeric—even though fermentation had actually reduced its curcuminoid content, a paradox suggesting that benefits may flow from biotransformed compounds, enhanced bioavailability or fermentation-derived metabolites rather than the parent phytochemicals alone. Fermented Panax notoginseng uniquely suppressed food intake and produced stronger weight reduction than the raw preparation, while fermented Polygonatum polysaccharides showed superior inhibition of adipogenesis in vitro.

The gut microbiota emerged as a central mediator of these effects. Across four in vivo studies that profiled host gut bacteria, fermented rhizome treatment consistently improved the ratio of Bacteroidetes to Firmicutes—a microbial signature repeatedly disrupted in obesity—and restored alpha diversity toward levels seen in normal-diet controls. Particularly striking was the enrichment of Akkermansia muciniphila, a mucus-degrading bacterium strongly associated with improved metabolic health and reduced gut permeability, which appeared in three independent studies using taxonomically distinct rhizome species. Fermented turmeric treatment also elevated faecal acetic, propionic and butyric acids—short-chain fatty acids that act through G-protein-coupled receptors to regulate lipid oxidation, insulin secretion and energy expenditure. Butyrate in particular was linked to the activation of thermogenic pathways in brown adipose tissue through upregulation of the metabolic enzymes ACSM3 and HADH, providing a direct microbiota-to-calorie-burning communication axis.

At the molecular level, the review identified at least six mechanistic axes of action. Suppression of adipogenesis—the process by which precursor cells mature into fat-storing adipocytes—was the most broadly shared, with multiple studies reporting downregulation of the master transcription factors PPAR-γ and C/EBPα and their downstream lipogenic enzymes. Conversely, lipolysis was enhanced through upregulation of HSL and ATGL and activation of PKA signalling. AMP-activated protein kinase, or AMPK, served as a central convergence node; in the most mechanistically complete study, fermented turmeric activated the AMPK–SIRT1–PGC-1α signalling triad, restoring mitochondrial oxidative capacity and energy expenditure while simultaneously suppressing endoplasmic reticulum stress and Nox4-mediated oxidative damage. Additional axes included improved insulin signalling via the PI3K/Akt pathway, attenuation of inflammatory cytokines including TNF-α, IL-6 and IL-1β, restoration of intestinal barrier integrity with reduced circulating endotoxin, and modulation of hypothalamic appetite regulation.

The metabolic results across the animal studies were substantive. All eight in vivo studies reported reductions in body weight gain or adipose tissue mass, and lipid profiles improved consistently, with reductions in serum and hepatic triglycerides in seven studies and HDL-cholesterol increases in four. One dose-response study documented that fermented turmeric extract at 200 and 500 milligrams per kilogram reduced weight gain by 12 and 22 percent respectively, while raising HDL-cholesterol by 53 to 67 percent. Glucose metabolism improved in the four studies assessing it, with reductions in fasting glucose, insulin and HOMA-IR, and thermogenic markers such as UCP-1 and adiponectin rose across several investigations.

The authors temper their enthusiasm with appropriate scientific caution. Using the OHAT framework, they rated the certainty of evidence as low or very low across all mechanistic axes, reflecting an entirely preclinical evidence base with predominantly unclear-to-high risk of bias in areas such as randomization and blinding. Substantial heterogeneity—five rhizome species, seven fermentation organisms, three product forms and multiple obesity models—prevented even a restricted quantitative meta-analysis. No human clinical data exist for these preparations. Nevertheless, the mechanistic coherence and cross-species consistency of the findings provide a preliminary foundation for the development of rhizome-based functional foods. The research team calls for randomized human intervention trials with standardized preparations, germ-free animal models to formally establish causal microbiota mechanisms, and bioactivity-guided fractionation to attribute specific effects to defined postbiotic compounds. If those trials succeed, the humble fermenting vat—humanity’s oldest food technology—may yet yield a new generation of evidence-based dietary tools against obesity.